Twist Bioscience Corporation presented an overview of its business at the J.P. Morgan 2026 Healthcare Conference, highlighting its proprietary silicon-based DNA synthesis platform and its diverse range of customizable solutions for therapeutics, diagnostics, industrial, research, agriculture, and applied markets. The company reported approximately $377 million in revenue for fiscal year 2025 and forecasts revenue between $425 million and $435 million for fiscal year 2026. Twist Bioscience’s customer base includes 19 of the top 20 pharmaceutical companies by 2024 revenue, 41 of the top 50 diagnostics companies, and 21 of the top 30 biotech companies globally. The company continues to expand its product offerings and market reach, with significant growth in areas such as protein expression, gene fragments, and library preparation. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Twist Bioscience Corporation published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.